ERBB2 and breast cancer: The recurrence rate in BC treated with HER2 therapy has been associated with drug resistance; however, this effect has not been completely clarified, due to the lack of rapid and accurate techniques that can easily quantify an appropriate dynamic HER2 range in patients [15].